Genmab — Marts 2022
-
Short positioner i danske aktier https://www.proinvestor.com/boards/101565/Short-positioner-i-danske-aktier
-
Dejligt at høre Monforte.
-
God morgen.
-
Olie:Olieprisen presser økonomien, forbrugerne og luftfarten https://proinvestor.com/index.php?p=debat_1&postid=101573#101574
-
Ruslands invasion af Ukraine har haft store konsekvenser for det globale aktiemarked. Hansen og Larsen er igen klar med et overblik over de vigtigste begivenheder i ugens afsnit af #Investeringspodcasten. Lyt med her, hvor de bl.a. kommer omkring stigninger i Vestas og Ørsted, oliepriserne og renterne. https://www.proinvestor.com/index.php?p=debat_1&postid=101575
-
Epcoritamab received FDA Orphan Drug Designation for Follicular Lymphoma https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=865921
-
Thx. New York & EL never sleeps
-
it is truly a sad story and unfortunately sleeping does not solve anything. We must fight for democracy which someone forgot to do in 2014 at the first movement....
-
Hope for better times
-
Aktier/middag: Vestas og Ørsted trækker ned - rederiaktie til tops https://proinvestor.com/investornyt/790145/aktier-middag-vestas-og-orsted-traekker-ned-rederiaktie-til-tops
-
Cami (camidanlumab tesirine)
The 12-month patient follow-up in the pivotal Phase 2 trial of Cami in Hodgkin lymphoma has completed. The Company has submitted the data in an abstract for an upcoming oncology conference and plans to meet with the FDA for a pre-BLA filing meeting.
The Phase 1b solid tumor trial of Cami in combination with pembrolizumab continues to dose escalate and in parallel has initiated a dose expansion cohort. -
Kort video: Helge Larsen kommenterer kort på den frygtelige situation i Ukraine og sanktionerne mod Rusland. Han taler om, hvad han gør som privatinvestor i krisetider, og hvad der er sikre havne i hans portefølje. Her kommer han bl.a. ind på energisektoren, laks og shipping. https://www.proinvestor.com/index.php?p=debat_1&postid=101591
-
Genmab gets a mid-to-high single-digit tiered royalty on net sales. https://ir.genmab.com/news-releases/news-release-details/genmab-and-adc-therapeutics-announce-amended-agreement/
-
ADC Therapeutics previously announced that Cami achieved an overall response rate of 86.5%, including a complete response rate of 48.6%, in Hodgkin lymphoma patients in this trial who had received a median of five prior lines of therapy. - Ganske flot i 6. linje. Bliver spændende hvad de nye data viser.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind